MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Biocompatibles UK Ltd / BTG Plc
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

BTG plc - Interim Management Statement Update - BTG plc (LSE: BTG), the specialist healthcare company, provides the following update for the period from 1 October 2012 to 31 January 2013 - BTGplc.com
BTG plc - Interim Management Statement Update

 

NewswireToday - /newswire/ - London, United Kingdom, 2013/01/31 - BTG plc (LSE: BTG), the specialist healthcare company, provides the following update for the period from 1 October 2012 to 31 January 2013 - BTGplc.com. LSE: BTG

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The Group’s trading during the period has been strong, with a particularly good performance from the Group’s acute care products. The Board currently anticipates that full year revenues for the year to 31 March 2013 will be around the top end of its guidance of £205m to £215m.

Whilst delivering strong financial results, the Group has also made good operational progress.

A New Drug Application seeking approval of Varisolve® (polidocanol endovenous microfoam (PEM)) as a comprehensive treatment for varicose veins will be submitted to the US Food & Drug Administration (FDA) within the next few days.

BTG’s interventional medicine business has made good progress. Humanitarian Use Device (HUD) designation was granted in the US in June 2012 for PRECISION Bead® and in December 2012 for PARAGON Bead®. HUD designation establishes that a medical device is intended to benefit patients in the treatment of a disease or condition that affects or is manifested in fewer than 4,000 individuals in the United States per year and it affords sponsors a faster review time and additional support from FDA reviewers.During H1 2013, BTG plans to submit Humanitarian Device Exemption (HDE) applications for both PARAGON Bead® and PRECISION Bead®, seeking authority to market both actively as drug-eluting bead treatments for intrahepatic cholangiocarcinoma and uveal melanoma with hypervascularised hepatic metastases respectively.

Good progress was also made with our partnered programmes. During the period, Zytiga® received US and EU label extensions to treat men with metastatic castration-resistant prostate cancer who have not received prior chemotherapy. In addition, Sanofi and its subsidiary Genzyme announced that the FDA had accepted for standard review a supplemental Biologics License Application (sBLA) file seeking approval of Lemtrada™ (alemtuzumab) for the treatment of relapsing multiple sclerosis. An FDA response on the application is expected during H2 2013. An EU regulatory opinion from the Committee for Medicinal Products for Human Use (CHMP)on Lemtrada™ for the treatment of relapsing multiple sclerosis is expected during Q2 2013.

Louise Makin, Chief Executive of BTG plc, said,“We have continued to make excellent operational and financial progress and now expect full year revenues to be around the top end of previous guidance. With the imminent submission of the Varisolve® NDA and the good progress in our beads business, we are on track with our strategic priorities and focused on executing our growth strategy.”

For further information contact:

BTG
Andy Burrows, Director of Investor Relations
T: +44 (0)20 7575 1741 / M: +44 (0)7990 530605

Rolf Soderstrom, Chief Financial Officer
T: +44 (0)20 7575 0000

Ben Atwell, FTI Consulting
T: +44 (0)20 7831 3113

About BTG
BTG (btgplc.com) is an international specialist healthcare company that is developing and commercialising products targeting critical care, cancer and other disorders. The company has diversified revenues from sales of its own marketed products and from royalties on partnered products, and is seeking to acquire new programmes and products to develop and market to specialist physicians.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Biocompatibles UK Ltd / BTG Plc

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


BTG plc - Interim Management Statement Update

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Press Office - BTGplc.com 
+44(0)20 7575 1513 media[.]btgplc.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Biocompatibles UK Ltd / BTG Plc securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Biocompatibles UK Ltd / BTG Plc / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen Data Presented During ENETS Annual Conference 2020 Capture New Patient and Healthcare Professional Insights in the Treatment of NETs
Global Pharmaceutical Contract Manufacturing Organization Market to Reach 2.14 Billion by 2024 Finds Frost & Sullivan
Ipsen’s Palovarotene Clinical Program in Fibrodysplasia Ossificans Progressiva Reaches Prespecified Interim Analysis Futility Criteria
Global Bio-based Chemicals Market is Expected to Grow At A CAGR of 16.67% by 2027 According to Inkwood Research
Global Diabetes Drugs Market Forecast 2019-2027 Reports Inkwood Research
Dysport® Now Approved in the UK for Symptomatic Treatment of Upper Limb Spasticity in Children with Cerebral Palsy
Human Microbiome Market to Reach .08 Billion by 2023, Powered by the High Growth in Over-the-Counter Probiotics Finds Frost & Sullivan
BASF Launches Hepacor in Switzerland for the Dietary Management of Non-Alcoholic Fatty Liver Disease
FDA Grants Priority Review to Genentech’s Risdiplam for Spinal Muscular Atrophy
Ipsen Presents New Analyses Utilizing Modern Data Mining Approaches At ISPOR Europe 2019
Global Opioids Drugs Market is Projected to Grow At a CAGR of 2.52% by 2027 Reports Inkwood Research
Global Bio-Based Chemicals Market Projected to Grow At a CAGR of 16.67% by 2027 Finds Inkwood Research
The Global Animal Nutrition Market Projected to Grow At a CAGR of 5.94% by 2027 Finds Inkwood Research
FDA Approves Genentech’s Rozlytrek (entrectinib) for People With ROS1-Positive, Metastatic Non-small Cell Lung Cancer
BTG to Invest in Chinese Medical Isotope Diagnosis and Treatment Company Chengdu New Radiomedicine Technology

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  Limelon Advertising, Co.





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)